Anika Therapeutics (ANIK) Q3 2024 earnings summary

Executive summary

• Completed sale of Arthrosurface and announced intent to divest Parcus Medical, shifting focus to core HA-based OA pain management and high-growth Regenerative Solutions targeting a $4B market.

• Global headcount reduced from 325 to 225 to optimize resources for core business areas.

• Revenue for Q3 2024 was $38.8M, down 7% year-over-year, with net loss of $29.9M driven by impairment and inventory write-downs.

• Strategic review led to narrowing of product focus, emphasizing high-growth, high-margin HA products and discontinuing underperforming assets.

• Share repurchase program of up to $40M initiated, with $5.3M spent by Q3 2024.

Financial highlights

• Q3 2024 revenue was $38.8M, down 7% year-over-year; OA Pain Management revenue fell 2% to $24.4M, Joint Preservation and Restoration down 11% to $12M, Non-Orthopedic down 24% to $2.4M.

• Gross margin was 4% (down from 60%) due to $23M+ impairment and inventory write-downs; adjusted gross margin was 65% (down from 66%).

• Net loss was $29.9M (vs. $6.6M prior year); adjusted net loss was $3.8M (vs. adjusted net income of $3.3M prior year).

• Adjusted EBITDA was $5.4M (14% margin), up from $4.7M (11% margin) year-over-year.

• Ended Q3 with $62.4M in cash and no debt.

Outlook and guidance

• 2024 revenue guidance: $117–$121M, flat to down 3% year-over-year; Commercial Channel expected to grow 14–19%, OEM Channel to decline 8–10%.

• 2025 Commercial Channel revenue projected to grow 12–18%; 2026–2027 growth expected at 20–30% annually, driven by Integrity and Hyalofast.

• OEM Channel revenue expected to decline 12–18% in 2025, stabilizing in 2026–2027.

• 2024 adjusted EBITDA guidance: $16–$18M; 2025+ adjusted EBITDA margins expected in low double digits, improving with Hyalofast launch.

• U.S. Cingal revenue not included in forecasts; updates pending FDA feedback.